US FDA warns drugmakers in India, China and the US for GMP issues
The US Food and Drug Administration (FDA) recently sent warning letters to companies in China, India, and the US for multiple violations of good manufacturing practices (GMP) related to the production of active pharmaceutical ingredients (APIs) and finished drugs.
comments(0)
5-min edit window · permanent after that